Skip to content
DataLookout
Menu

NCT04387227

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 29 versions: 26 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 20, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints revised (3)
    • Primary endpoints revised (2)
    • Site details revised
  2. Minor Trial status: Active, Not Recruiting to Completedv28
  3. Minor Primary completion date changed from estimate of Jun 30, 2025 to Sep 12, 2025
    • Study completion date: Dec 31, 2025 to Jun 1, 2026
    v27
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Secondary endpoints: 4 to 3
    • Site details revised
    v26
  5. Notable Primary completion date: Dec 31, 2024 to Jun 30, 2025v25
Show 20 earlier versionsHide 20 earlier versions
  1. Notable Primary completion date: Apr 3, 2024 to Dec 31, 2024
    • Study completion date: Apr 3, 2025 to Dec 31, 2025
    v24
  2. Notable Eligibility criteria expanded, about 12 words
    • Interventions: Carboplatin (Drug), Pembrolizumab (Biological) to Biospecimen Collection (Procedure), Carboplatin (Drug), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)…
    • Study description expanded, about 22 words
    v23
  3. Notable Primary completion date: Apr 3, 2023 to Apr 3, 2024
    • Study completion date: Apr 3, 2024 to Apr 3, 2025
    v20
  4. Notable Eligibility criteria shortened, about 10 wordsv19
  5. Notable Eligibility criteria expanded, about 33 wordsv18
  6. Minor Start date changed from estimate of Jun 26, 2021 to Mar 18, 2021v17
  7. Notable Start date: May 26, 2021 to Jun 26, 2021v16
  8. Notable Start date: Apr 24, 2021 to May 26, 2021v15
  9. Notable Start date: Mar 24, 2021 to Apr 24, 2021v14
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 11, 2021 to Mar 24, 2021
    • Site details revised
    v13
  11. Notable Eligibility criteria expanded, about 3 words
    • Start date: Feb 11, 2021 to Mar 11, 2021
    • Study description revised
    v12
  12. Notable Start date: Jan 9, 2021 to Feb 11, 2021v10
  13. Notable Start date: Dec 9, 2020 to Jan 9, 2021v9
  14. Notable Start date: Nov 5, 2020 to Dec 9, 2020v8
  15. Notable Start date: Oct 3, 2020 to Nov 5, 2020v7
  16. Notable Start date: Sep 3, 2020 to Oct 3, 2020v6
  17. Notable Start date: Aug 1, 2020 to Sep 3, 2020v5
  18. Notable Start date: Jul 1, 2020 to Aug 1, 2020v4
  19. Notable Start date: Jun 1, 2020 to Jul 1, 2020v3
  20. Minor Site contact updatedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Rate of Radiographic Recurrence
Timeframe: At 6 months
Progression Free Survival
Timeframe: Up to 2 years

Secondary (3)

Programmed Cell Death Ligand 1 (PD-L1) Expression
Changes in T Cell Activation
Overall Survival

Arms and interventions

Treatment (carboplatin, pembrolizumab)Experimental

Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection on the trial.

Drugs: Carboplatin

Biologicals: Pembrolizumab

Procedures: Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States